Rapid Local Ischemic Postconditioning in Acute Ischemic Stroke
Launched by SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE'S HOSPITAL · Mar 9, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new method called rapid local ischemic postconditioning (RL-IPostC) to see if it can help prevent brain swelling in patients who have experienced an acute ischemic stroke. During the trial, researchers will temporarily block blood flow to the brain using a balloon technique right after a procedure called mechanical thrombectomy, which is used to remove a blockage in the brain’s blood vessels. The goal is to help the brain adjust better to the changes in blood flow and protect it from damage.
To participate in this trial, individuals must be at least 18 years old and showing symptoms of an acute ischemic stroke. They should have a certain level of stroke severity and need to be eligible for treatment within 24 hours of the stroke starting. Participants will be closely monitored to assess the safety and effectiveness of the treatment. This trial is not yet recruiting, but it aims to find the best approach for this new technique to eventually help improve outcomes for stroke patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years old
- • 2. Presenting with symptoms consistent with acute ischemic stroke
- • 3. Pre-stroke mRS score 0-1
- • 4. Baseline NIHSS score≥6
- • 5. Endovascular treatment can be initiated (femoral puncture) within 24 hours from stroke onset (stroke onset time is defined as last known well time)
- • 6. Occlusion of the intracranial internal carotid artery, or the middle cerebral artery(M1 or M2) confirmed by CTA or MRA, and is the culprit artery
- • 7. Alberta Stroke Program Early CT Score (ASPECTS) (based on non-contrast CT) \>5 on noncontrast computed tomography (NCCT) for stroke onset time less than 6 hours, infarct Core \< 70 ml (defined as rCBF \<30% on CT perfusion) and mismatch ratio \> 1.2 (penumbra defined as Tmax \>6 seconds volume) for stroke onset time between 6 and 24 hours.
- • 8. Embolism verified as the etiology of occluded artery and mTICI 2b or 3 regained after mechanical thrombectomy
- • 9. Informed consent signed
- Exclusion Criteria:
- • 1. Stenosis of the proximal middle cerebral artery, internal carotid artery, or common carotid artery (≥50%) of the culprit artery
- • 2. Multiple vascular embolism on different pathways (not refers to the ipsilateral middle artery and anterior artery)
- • 3. Pre ischemic stroke or transient ischemic attack within past 3 months
- • 4. The expected survival time is less than 6 months, could not be followed at 90 days (such as patient with malignant tumor)
- • 5. Currently pregnant, mental disease, advanced hepatic and renal insufficiency, severe heart failure
- • 6. Participation in other interventional randomized clinical trials that may confound the outcome assessment of the trial
- • 7. Other circumstances that the investigator considers inappropriate for this trial
About Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Shanghai Jiao Tong University Affiliated Sixth People's Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare and innovative clinical research. As a prominent clinical trial sponsor, the hospital leverages its strong academic foundation and multidisciplinary expertise to conduct high-quality studies that aim to enhance therapeutic options and improve patient outcomes. The institution is dedicated to fostering collaboration between researchers, healthcare professionals, and industry partners, ensuring the rigorous application of ethical standards and scientific integrity in all its clinical trials. Through its state-of-the-art facilities and a patient-centered approach, the hospital plays a vital role in advancing medical knowledge and contributing to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yueqi Zhu, MD
Principal Investigator
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported